The estimated Net Worth of Steven M Paul is at least $65.7 Milion dollars as of 23 February 2024. Steven Paul owns over 31,518 units of Karuna Therapeutics Inc stock worth over $13,890,461 and over the last 19 years he sold KRTX stock worth over $41,762,013. In addition, he makes $10,050,700 as Chairman of the Board, President a Chief Executive Officer at Karuna Therapeutics Inc.
Steven has made over 35 trades of the Karuna Therapeutics Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently he exercised 31,518 units of KRTX stock worth $599,788 on 23 February 2024.
The largest trade he's ever made was exercising 292,207 units of Karuna Therapeutics Inc stock on 29 June 2020 worth over $32,143. On average, Steven trades about 10,944 units every 74 days since 2005. As of 23 February 2024 he still owns at least 42,114 units of Karuna Therapeutics Inc stock.
You can see the complete history of Steven Paul stock trades at the bottom of the page.
Dr. Steven M. Paul M.D. serves as Chairman of the Board, President, Chief Executive Officer of the Company. Previously, Dr. Paul was the President and Chief Executive Officer of Voyager Therapeutics, Inc. from September 2014 to August 2018. Dr. Paul also serves as a venture partner at Third Rock Ventures, LLC, a life sciences venture capital firm. Together with Third Rock, Dr. Paul co-founded Sage Therapeutics, Inc. and Voyager Therapeutics, Inc. From August 2010 to September 2014, Dr. Paul was a professor of neuroscience, psychiatry and pharmacology at Weill Cornell Medical College. Prior to that, from 1993 to 2010, Dr. Paul held several key positions at Eli Lilly and Company, or Eli Lilly, including Executive Vice President for Science and Technology, President of the Lilly Research Laboratories, Vice President of Neuroscience (CNS) Research and Group Vice President of Discovery Research. Prior to Eli Lilly, from 1988 to 1993, Dr. Paul served as the Scientific Director of the National Institute of Mental Health, or NIMH. From 1982 to 1988 Dr. Paul served as a laboratory branch chief and tenured investigator at NIMH. Dr. Paul also served as Medical Director in the Commissioned Corps of the United States Public Health Service. Dr. Paul is an elected fellow of the American Association for the Advancement of Science and a member of the National Academy of Medicine. Dr. Paul is currently on the board of directors or is a trustee of several organizations, including Sage Therapeutics, Inc. (NASDAQ: SAGE), Voyager Therapeutics, Inc. (NASDAQ: VYGR), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) and the Foundation for the National Institutes of Health, or FNIH. In the past five years, Dr. Paul also served on the board of Sigma Aldrich Corporation (NASDAQ: SIAL). Dr. Paul was appointed by the Secretary of the Department of Health and Human Services as a member of the advisory committee to the Director of the NIH from 2001 to 2006.
As the Chairman of the Board, President a Chief Executive Officer of Karuna Therapeutics Inc, the total compensation of Steven Paul at Karuna Therapeutics Inc is $10,050,700. There are no executives at Karuna Therapeutics Inc getting paid more.
Steven's mailing address filed with the SEC is C/O KARUNA THERAPEUTICS, INC., 99 HIGH STREET, 26TH FLOOR, BOSTON, MA, 02110.
Over the last 5 years, insiders at Karuna Therapeutics Inc have traded over $496,938,545 worth of Karuna Therapeutics Inc stock and bought 1,501,936 units worth $53,814,390 . The most active insiders traders include Health Llc Pure Tech, James Healy a Robert Nelsen. On average, Karuna Therapeutics Inc executives and independent directors trade stock every 12 days with the average trade being worth of $18,341,187. The most recent stock trade was executed by Stephen K. Brannan on 8 March 2024, trading 7,500 units of KRTX stock currently worth $636,600.
we are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. our pipeline is built on the broad therapeutic potential of our lead product candidate, karxt, an oral modulator of muscarinic receptors that are located both in the central nervous system, or cns, and various peripheral tissues. karxt is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the cns. we have assembled a team with extensive expertise in the research, development and commercialization of numerous cns agents, as well as deep familiarity with the biology of neuropsychiatric disorders, such as schizophrenia and ad, including the role of muscarinic receptors in their potential treatment. we will leverage this expertise to develop a pip
Karuna Therapeutics Inc executives and other stock owners filed with the SEC include: